Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

GRDN vs MCK vs CAH vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GRDN
Guardian Pharmacy Services, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$2.30B
5Y Perf.+116.0%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+52.2%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+67.6%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+38.9%

GRDN vs MCK vs CAH vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GRDN logoGRDN
MCK logoMCK
CAH logoCAH
CVS logoCVS
IndustryMedical - DistributionMedical - DistributionMedical - DistributionMedical - Healthcare Plans
Market Cap$2.30B$92.15B$43.59B$111.40B
Revenue (TTM)$1.46B$403.43B$250.55B$407.90B
Net Income (TTM)$53M$4.76B$1.56B$2.93B
Gross Margin20.2%3.6%3.7%13.9%
Operating Margin6.4%1.5%0.9%1.5%
Forward P/E29.6x19.3x17.9x12.2x
Total Debt$37M$7.39B$9.35B$93.59B
Cash & Equiv.$66M$5.69B$3.87B$8.51B

GRDN vs MCK vs CAH vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GRDN
MCK
CAH
CVS
StockSep 24May 26Return
Guardian Pharmacy S… (GRDN)100216.0+116.0%
McKesson Corporation (MCK)100152.2+52.2%
Cardinal Health, In… (CAH)100167.6+67.6%
CVS Health Corporat… (CVS)100138.9+38.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: GRDN vs MCK vs CAH vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GRDN leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. CVS Health Corporation is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. CAH also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
GRDN
Guardian Pharmacy Services, Inc.
The Growth Play

GRDN carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
  • 17.9% revenue growth vs CAH's -1.9%
  • 3.6% margin vs CAH's 0.6%
  • +40.5% vs MCK's +4.6%
Best for: growth exposure
MCK
McKesson Corporation
The Long-Run Compounder

MCK is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 348.1% 10Y total return vs CAH's 160.8%
  • PEG 0.49 vs GRDN's 1.58
Best for: long-term compounding and valuation efficiency
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Lower volatility, beta 0.03, current ratio 0.94x
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs GRDN's 1.04
Best for: income & stability and sleep-well-at-night
CVS
CVS Health Corporation
The Insurance Pick

CVS is the #2 pick in this set and the best alternative if value and dividends is your priority.

  • Lower P/E (12.2x vs 17.9x)
  • 3.1% yield, vs CAH's 1.1%, (1 stock pays no dividend)
Best for: value and dividends
See the full category breakdown
CategoryWinnerWhy
GrowthGRDN logoGRDN17.9% revenue growth vs CAH's -1.9%
ValueCVS logoCVSLower P/E (12.2x vs 17.9x)
Quality / MarginsGRDN logoGRDN3.6% margin vs CAH's 0.6%
Stability / SafetyCAH logoCAHBeta 0.03 vs GRDN's 1.04
DividendsCVS logoCVS3.1% yield, vs CAH's 1.1%, (1 stock pays no dividend)
Momentum (1Y)GRDN logoGRDN+40.5% vs MCK's +4.6%
Efficiency (ROA)GRDN logoGRDN13.4% ROA vs CVS's 1.1%, ROIC 35.8% vs 5.0%

GRDN vs MCK vs CAH vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GRDNGuardian Pharmacy Services, Inc.
FY 2025
Corporate Segment
100.0%$1.4B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

GRDN vs MCK vs CAH vs CVS — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGRDNLAGGINGCAH

Income & Cash Flow (Last 12 Months)

GRDN leads this category, winning 4 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 280.2x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 0.6% (CAH). On growth, CAH holds the edge at +11.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$1.5B$403.4B$250.5B$407.9B
EBITDAEarnings before interest/tax$112M$6.8B$3.2B$10.5B
Net IncomeAfter-tax profit$53M$4.8B$1.6B$2.9B
Free Cash FlowCash after capex$70M$6.0B$4.4B$7.4B
Gross MarginGross profit ÷ Revenue+20.2%+3.6%+3.7%+13.9%
Operating MarginEBIT ÷ Revenue+6.4%+1.5%+0.9%+1.5%
Net MarginNet income ÷ Revenue+3.6%+1.2%+0.6%+0.7%
FCF MarginFCF ÷ Revenue+4.8%+1.5%+1.8%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+2.2%+6.0%+11.0%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+40.0%+37.0%-19.5%+63.1%
GRDN leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

CVS leads this category, winning 4 of 7 comparable metrics.

At 28.7x trailing earnings, CAH trades at a 54% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs GRDN's 2.48x — a lower PEG means you pay less per unit of expected earnings growth.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Market CapShares × price$2.3B$92.1B$43.6B$111.4B
Enterprise ValueMkt cap + debt − cash$2.3B$93.8B$49.1B$196.5B
Trailing P/EPrice ÷ TTM EPS46.51x29.25x28.72x62.81x
Forward P/EPrice ÷ next-FY EPS est.29.62x19.28x17.94x12.19x
PEG RatioP/E ÷ EPS growth rate2.48x0.75x
EV / EBITDAEnterprise value multiple20.40x18.74x16.01x13.11x
Price / SalesMarket cap ÷ Revenue1.59x0.26x0.20x0.28x
Price / BookPrice ÷ Book value/share10.54x1.47x
Price / FCFMarket cap ÷ FCF28.47x17.63x23.56x14.27x
CVS leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

GRDN leads this category, winning 7 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $4 for CVS. GRDN carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), GRDN scores 6/9 vs CVS's 5/9, reflecting solid financial health.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity+25.4%+3.0%+3.9%
ROA (TTM)Return on assets+13.4%+5.7%+2.8%+1.1%
ROICReturn on invested capital+35.8%+5.4%+33.8%+5.0%
ROCEReturn on capital employed+41.5%+30.5%+19.2%+6.1%
Piotroski ScoreFundamental quality 0–96665
Debt / EquityFinancial leverage0.17x1.24x
Net DebtTotal debt minus cash-$28M$1.7B$5.5B$85.1B
Cash & Equiv.Liquid assets$66M$5.7B$3.9B$8.5B
Total DebtShort + long-term debt$37M$7.4B$9.3B$93.6B
Interest CoverageEBIT ÷ Interest expense129.16x33.79x6.38x2.11x
GRDN leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — GRDN and MCK and CAH each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $11,700 for CVS. Over the past 12 months, GRDN leads with a +40.5% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs CVS's 11.0% — a key indicator of consistent wealth creation.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date+22.9%-8.5%-9.5%+10.6%
1-Year ReturnPast 12 months+40.5%+4.6%+22.0%+34.7%
3-Year ReturnCumulative with dividends+126.7%+106.4%+127.3%+36.6%
5-Year ReturnCumulative with dividends+126.8%+286.9%+235.7%+17.0%
10-Year ReturnCumulative with dividends+126.7%+348.1%+160.8%+3.5%
CAGR (3Y)Annualised 3-year return+31.4%+27.3%+31.5%+11.0%
Evenly matched — GRDN and MCK and CAH each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 5001.04x0.04x0.03x0.05x
52-Week HighHighest price in past year$41.36$999.00$233.60$88.63
52-Week LowLowest price in past year$19.17$637.00$137.75$58.35
% of 52W HighCurrent price vs 52-week peak+87.7%+75.3%+79.3%+98.5%
RSI (14)Momentum oscillator 0–10047.416.233.269.3
Avg Volume (50D)Average daily shares traded461K757K1.7M7.4M
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: GRDN as "Buy", MCK as "Buy", CAH as "Buy", CVS as "Buy". Consensus price targets imply 34.8% upside for CAH (target: $250) vs 4.7% for GRDN (target: $38). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$38.00$1006.50$249.67$95.20
# AnalystsCovering analysts3313341
Dividend YieldAnnual dividend ÷ price+0.4%+1.1%+3.1%
Dividend StreakConsecutive years of raises017200
Dividend / ShareAnnual DPS$2.69$2.04$2.67
Buyback YieldShare repurchases ÷ mkt cap+1.3%+3.4%+1.8%0.0%
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

GRDN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 1 (Valuation Metrics). 3 tied.

Best OverallGuardian Pharmacy Services,… (GRDN)Leads 2 of 6 categories
Loading custom metrics...

GRDN vs MCK vs CAH vs CVS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is GRDN or MCK or CAH or CVS a better buy right now?

For growth investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GRDN or MCK or CAH or CVS?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — GRDN or MCK or CAH or CVS?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to +17. 0% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: MCK returned +348. 1% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GRDN or MCK or CAH or CVS?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 2969% more volatile than CAH relative to the S&P 500. On balance sheet safety, Guardian Pharmacy Services, Inc. (GRDN) carries a lower debt/equity ratio of 17% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — GRDN or MCK or CAH or CVS?

By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.

(GRDN) is pulling ahead at 17. 9% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GRDN or MCK or CAH or CVS?

Guardian Pharmacy Services, Inc.

(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 1. 0% for CAH. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GRDN or MCK or CAH or CVS more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CVS Health Corporation (CVS) trades at 12. 2x forward P/E versus 29. 6x for Guardian Pharmacy Services, Inc. — 17. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 34. 8% to $249. 67.

08

Which pays a better dividend — GRDN or MCK or CAH or CVS?

In this comparison, CVS (3.

1% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.

09

Is GRDN or MCK or CAH or CVS better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, GRDN: +126. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GRDN and MCK and CAH and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GRDN is a small-cap high-growth stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CAH, CVS pay a dividend while GRDN, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

GRDN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 12%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GRDN and MCK and CAH and CVS on the metrics below

Revenue Growth>
%
(GRDN: 2.2% · MCK: 6.0%)
P/E Ratio<
x
(GRDN: 46.5x · MCK: 29.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.